• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2013年中国癌症发病率及死亡率估算

Estimates of cancer incidence and mortality in China, 2013.

作者信息

Zheng Rongshou, Zeng Hongmei, Zhang Siwei, Chen Wanqing

机构信息

National Central Cancer Registry, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P. R. China.

出版信息

Chin J Cancer. 2017 Aug 17;36(1):66. doi: 10.1186/s40880-017-0234-3.

DOI:10.1186/s40880-017-0234-3
PMID:28818111
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5561600/
Abstract

INTRODUCTION

Population-based cancer registration data are collected by the National Central Cancer Registry in China every year. Cancer incident cases and cancer deaths in 2013 were analyzed.

METHODS

Through the procedure of quality control, reported data from 255 registries were accepted to establish the national database for cancer estimates. Incidences and mortalities were calculated with stratification by area (urban/rural), sex (male/female), age group (0, 1-4, 5-9, 10-14 … 80-84, and 85-year-old and above), and cancer site. The structure of Segi's population was used for the calculation of age-standardized rates (ASR). Top 10 most common cancers and leading causes of cancer deaths were listed.

RESULTS

In 2013, 3,682,200 new cancer cases and 2,229,300 cancer deaths were estimated in China based on the pooled data from 255 cancer registries, covering 16.65% of the national population. The incidence was 270.59/100,000, with an ASR of 186.15/100,000; the mortality was 166.83/100,000, with an ASR of 108.94/100,000. The top 10 most common cancer sites were the lung, stomach, liver, colorectum, female breast, esophagus, thyroid, cervix, brain, and pancreas. The ten leading causes of cancer deaths were lung cancer, liver cancer, gastric cancer, esophageal cancer, colorectal cancer, pancreatic cancer, female breast cancer, brain tumor, leukemia, and lymphoma.

CONCLUSIONS

Cancer leaves serious disease burden in China with high incidence and mortality. Lung cancer was the most common cancer and the leading cause of cancer death in China. Efficient control strategy is needed, especially for major cancers.

摘要

引言

中国国家癌症中心每年都会收集基于人群的癌症登记数据。对2013年的癌症发病病例和癌症死亡情况进行了分析。

方法

通过质量控制程序,接受了来自255个登记处上报的数据,以建立全国癌症估计数据库。发病率和死亡率按地区(城市/农村)、性别(男/女)、年龄组(0岁、1 - 4岁、5 - 9岁、10 - 14岁……80 - 84岁以及85岁及以上)和癌症部位进行分层计算。采用Segi人口结构计算年龄标准化率(ASR)。列出了十大最常见癌症及癌症死亡的主要原因。

结果

基于255个癌症登记处的汇总数据估计,2013年中国有3682200例新发癌症病例和2229300例癌症死亡病例,覆盖全国人口的16.65%。发病率为270.59/10万,年龄标准化率为186.15/10万;死亡率为166.83/10万,年龄标准化率为108.94/10万。十大最常见癌症部位为肺癌、胃癌、肝癌、结直肠癌、女性乳腺癌、食管癌、甲状腺癌、宫颈癌、脑癌和胰腺癌。癌症死亡的十大主要原因是肺癌、肝癌、胃癌、食管癌、结直肠癌、胰腺癌、女性乳腺癌、脑肿瘤、白血病和淋巴瘤。

结论

癌症在中国造成了严重的疾病负担,发病率和死亡率都很高。肺癌是中国最常见的癌症,也是癌症死亡的主要原因。需要有效的控制策略,尤其是针对主要癌症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/5561600/54c82bd402e1/40880_2017_234_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/5561600/c3fc45987dc4/40880_2017_234_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/5561600/5ddbef4d69a2/40880_2017_234_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/5561600/4815a503d248/40880_2017_234_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/5561600/2726415d3109/40880_2017_234_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/5561600/c6fe56ef2799/40880_2017_234_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/5561600/54c82bd402e1/40880_2017_234_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/5561600/c3fc45987dc4/40880_2017_234_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/5561600/5ddbef4d69a2/40880_2017_234_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/5561600/4815a503d248/40880_2017_234_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/5561600/2726415d3109/40880_2017_234_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/5561600/c6fe56ef2799/40880_2017_234_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/5561600/54c82bd402e1/40880_2017_234_Fig6_HTML.jpg

相似文献

1
Estimates of cancer incidence and mortality in China, 2013.2013年中国癌症发病率及死亡率估算
Chin J Cancer. 2017 Aug 17;36(1):66. doi: 10.1186/s40880-017-0234-3.
2
The updated incidences and mortalities of major cancers in China, 2011.2011年中国主要癌症的最新发病率和死亡率。
Chin J Cancer. 2015 Sep 14;34(11):502-7. doi: 10.1186/s40880-015-0042-6.
3
The incidence and mortality of major cancers in China, 2012.2012年中国主要癌症的发病率和死亡率。
Chin J Cancer. 2016 Aug 2;35(1):73. doi: 10.1186/s40880-016-0137-8.
4
[Report of Cancer Incidence and Mortality in China, 2014].《2014年中国癌症发病与死亡报告》
Zhonghua Zhong Liu Za Zhi. 2018 Jan 23;40(1):5-13. doi: 10.3760/cma.j.issn.0253-3766.2018.01.002.
5
National cancer incidence and mortality in China, 2012.2012年中国国家癌症发病率与死亡率
Chin J Cancer Res. 2016 Feb;28(1):1-11. doi: 10.3978/j.issn.1000-9604.2016.02.08.
6
[Incidence and mortality of cancers appeared in the Hebei provincial cancer registry system in 2011].2011年河北省癌症登记系统中出现的癌症发病率和死亡率
Zhonghua Liu Xing Bing Xue Za Zhi. 2015 Aug;36(8):846-51.
7
[Report of cancer epidemiology in China, 2015].《2015年中国癌症流行病学报告》
Zhonghua Zhong Liu Za Zhi. 2019 Jan 23;41(1):19-28. doi: 10.3760/cma.j.issn.0253-3766.2019.01.005.
8
[Incidence and mortality of bladder cancer in China, 2014].[2014年中国膀胱癌的发病率和死亡率]
Zhonghua Zhong Liu Za Zhi. 2018 Sep 23;40(9):647-652. doi: 10.3760/cma.j.issn.0253-3766.2018.09.002.
9
Report of cancer incidence and mortality in China, 2010.中国癌症发病率和死亡率报告,2010 年。
Ann Transl Med. 2014 Jul;2(7):61. doi: 10.3978/j.issn.2305-5839.2014.04.05.
10
Report of incidence and mortality in China cancer registries, 2009.中国癌症登记地区 2009 年肿瘤登记发病与死亡报告
Chin J Cancer Res. 2013 Feb;25(1):10-21. doi: 10.3978/j.issn.1000-9604.2012.12.04.

引用本文的文献

1
Comparison of recurrence patterns between patients with thoracic esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and postoperative adjuvant chemoradiotherapy.接受新辅助放化疗和术后辅助放化疗的胸段食管鳞状细胞癌患者复发模式的比较。
Front Oncol. 2025 Jun 16;15:1604808. doi: 10.3389/fonc.2025.1604808. eCollection 2025.
2
The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma.经动脉化疗栓塞联合肝动脉灌注化疗、乐伐替尼和程序性死亡受体1抑制剂治疗不可切除肝细胞癌患者显示出显著临床疗效。
Cancer Manag Res. 2025 Feb 6;17:239-247. doi: 10.2147/CMAR.S481242. eCollection 2025.
3

本文引用的文献

1
Cancer incidence and mortality in China, 2013.2013年中国的癌症发病率和死亡率
Cancer Lett. 2017 Aug 10;401:63-71. doi: 10.1016/j.canlet.2017.04.024. Epub 2017 May 3.
2
The incidence and mortality of major cancers in China, 2012.2012年中国主要癌症的发病率和死亡率。
Chin J Cancer. 2016 Aug 2;35(1):73. doi: 10.1186/s40880-016-0137-8.
3
National cancer incidence and mortality in China, 2012.2012年中国国家癌症发病率与死亡率
Current and projected incidence rates of pancreatic cancer in 43 countries: an analysis of the Cancer Incidence in Five Continents database.
43个国家胰腺癌的当前及预计发病率:对《五大洲癌症发病率》数据库的分析
BMJ Open Gastroenterol. 2025 Jan 21;12(1):e001544. doi: 10.1136/bmjgast-2024-001544.
4
The Long Noncoding RNA DUXAP8 Facilitates the Malignant Progression of Colon Cancer via the microRNA-378a-3p/FOXQ1 Axis.长链非编码RNA DUXAP8通过微小RNA-378a-3p/FOXQ1轴促进结肠癌的恶性进展。
Gut Liver. 2025 Mar 15;19(2):219-235. doi: 10.5009/gnl240178. Epub 2024 Nov 20.
5
Cost-effectiveness analysis of trifluridine/tipiracil in the treatment of heavily pretreated metastatic gastric cancer from the perspective of Chinese healthcare system.从中国医疗体系角度评估替氟尿苷/替匹嘧啶治疗广泛预处理转移性胃癌的成本效果分析。
BMJ Open. 2024 Nov 7;14(11):e080846. doi: 10.1136/bmjopen-2023-080846.
6
Thyroid Hormone Biomonitoring: A Review on Their Metabolism and Machine-Learning Based Analysis on Effects of Endocrine Disrupting Chemicals.甲状腺激素生物监测:关于其代谢及基于机器学习分析内分泌干扰化学物质影响的综述
Environ Health (Wash). 2024 Mar 4;2(6):350-372. doi: 10.1021/envhealth.3c00184. eCollection 2024 Jun 21.
7
Construction and evaluation of a polygenic hazard score for prognostic assessment in localized gastric cancer.用于局部胃癌预后评估的多基因风险评分的构建与评估
Fundam Res. 2022 Nov 9;4(5):1331-1338. doi: 10.1016/j.fmre.2022.09.031. eCollection 2024 Sep.
8
promotes gastric cancer through CagA-mediated mitochondrial cholesterol accumulation by targeting CYP11A1 redistribution.通过靶向CYP11A1重新分布,由CagA介导的线粒体胆固醇积累促进胃癌。
Int J Biol Sci. 2024 Jul 15;20(10):4007-4028. doi: 10.7150/ijbs.96425. eCollection 2024.
9
Wnt/β-catenin-driven EMT regulation in human cancers.Wnt/β-catenin 驱动的人类癌症中的 EMT 调控。
Cell Mol Life Sci. 2024 Feb 9;81(1):79. doi: 10.1007/s00018-023-05099-7.
10
Dosimetric comparison between stereotactic body radiotherapy and carbon-ion radiation therapy for prostate cancer.立体定向体部放射治疗与碳离子放射治疗在前列腺癌治疗中的剂量学比较。
Quant Imaging Med Surg. 2023 Oct 1;13(10):6965-6978. doi: 10.21037/qims-23-340. Epub 2023 Sep 22.
Chin J Cancer Res. 2016 Feb;28(1):1-11. doi: 10.3978/j.issn.1000-9604.2016.02.08.